ergoline and Dyspnea

ergoline has been researched along with Dyspnea* in 2 studies

Other Studies

2 other study(ies) available for ergoline and Dyspnea

Article	Year
Aortic regurgitation associated with cabergoline therapy. British journal of hospital medicine (London, England : 2005), 2008, Volume: 69, Issue:1 Topics: Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Dyspnea; Ergolines; Humans; Lewy Body Disease; Male; Middle Aged; Ultrasonography	2008
Pleural fibrosis associated with dihydroergocryptine treatment. Acta neurologica Scandinavica, 2000, Volume: 101, Issue:4 This is the first report of a histologically confirmed pleuropulmonary fibrosis (PPF) associated with the dopamine agonist dihydroergocryptine.. A 67-year-old male patient with Parkinson's disease developed a severe restrictive pulmonary disorder with dyspnea and nonproductive cough after a daily intake of 45 mg dihydroergocryptine for 2 years. After changing the dopamine agonist to the non-ergoline substance pramipexole, marked improvement of the clinical symptoms of PPF occurred, while radiological signs showed only a moderate decrease.. PPF is a possibly fatal complication. Chest X-rays and specific pneumological diagnostics should be done if typical symptoms or nonspecific signs of PPF occur while a patient is on treatment with an ergoline dopamine agonist. Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cough; Dopamine Agonists; Dyspnea; Ergolines; Humans; Male; Parkinson Disease; Pramipexole; Pulmonary Fibrosis; Thiazoles	2000

Article

Year

Aortic regurgitation associated with cabergoline therapy.

British journal of hospital medicine (London, England : 2005), 2008, Volume: 69, Issue:1

Topics: Aortic Valve Insufficiency; Cabergoline; Dopamine Agonists; Dyspnea; Ergolines; Humans; Lewy Body Disease; Male; Middle Aged; Ultrasonography

2008

Pleural fibrosis associated with dihydroergocryptine treatment.

Acta neurologica Scandinavica, 2000, Volume: 101, Issue:4

This is the first report of a histologically confirmed pleuropulmonary fibrosis (PPF) associated with the dopamine agonist dihydroergocryptine.. A 67-year-old male patient with Parkinson's disease developed a severe restrictive pulmonary disorder with dyspnea and nonproductive cough after a daily intake of 45 mg dihydroergocryptine for 2 years. After changing the dopamine agonist to the non-ergoline substance pramipexole, marked improvement of the clinical symptoms of PPF occurred, while radiological signs showed only a moderate decrease.. PPF is a possibly fatal complication. Chest X-rays and specific pneumological diagnostics should be done if typical symptoms or nonspecific signs of PPF occur while a patient is on treatment with an ergoline dopamine agonist.

Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cough; Dopamine Agonists; Dyspnea; Ergolines; Humans; Male; Parkinson Disease; Pramipexole; Pulmonary Fibrosis; Thiazoles

2000